



Influential. International. Indispensable

[Click here to subscribe](#)


THE LANCET.com

[Home](#) | [Advanced & Citation Search](#) | [Help](#)

Search


[The Journals](#)
[Article Collections](#)
[Authors](#)
[Jobs & Conferences](#)
[About Us](#)
[My Account](#)
[Early Online Publication](#) | [The Lancet](#) | [The Lancet Neurology](#) | [The Lancet Oncology](#) | [The Lancet Infectious Diseases](#) | [Your Comments](#)
[Current Issue](#)
[Back Issues](#)
[Special Issues](#)
[Fast Track](#)
[Responses](#)
[Protocol Reviews](#)

Comments on:

Articles:

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial

The Lancet - Vol. 365, Number 9471, 07 May 2005, Pages 1621-1628
[Summary](#) | [Full Text](#)

[Add your comments to this article](#)


Dr. Vasquez

 [Log out](#)
 [Premium Content](#)
 [Subscriptions](#)
 [Email Alerts](#)
Viewing 1- of NaN Comments

Comments Page: [1]

[Subphysiologic Doses of Vitamin D are Subtherapeutic: Comment on the Study by The Record Trial Group](#)

Alex Vasquez, May 06 2005

Subphysiologic Doses of Vitamin D are Subtherapeutic: Comment on the Study by The Record Trial Group

May 06 2005

Alex Vasquez, *Researcher, Private Practice, and Researcher at Biotics Research Corporation.*



The Lancet is now mobile!
[Click here](#)

You can now
 submit your
 paper online

Dear Editor, Based on recently published research, it is clear that the study by The Record Trial Group [1] on vitamin D and calcium in the prevention of fractures suffered from at least four important shortcomings which negatively skewed their results. First, and most important, the dose of vitamin D used in their study (800 IU/d) is subphysiologic and would therefore not be expected to produce a clinically meaningful effect. The physiologic requirement for vitamin D was determined scientifically in a recent study by Heaney and colleagues [2], who showed that healthy men utilize 3,000 to 5,000 IU of cholecalciferol per day, and several recent clinical trials have been published documenting the safety and effectiveness of administering vitamin D in physiologic doses of at least 4,000 IU per day.[3-5] In fact, studies have shown a dose-response relationship with vitamin D supplementation [6], and low doses (e.g., 600 IU) are clearly less effective than higher doses in the physiologic range (e.g., 4,000 IU).[5] It is important to note that the commonly used dose of vitamin D at 800 IU per day was not determined scientifically; rather this amount was determined arbitrarily before sufficient scientific methodology was available.[2,7] Given that the commonly recommended daily intake of

Read
*The Lancet
 Oncology*
 in a whole
 new way...

vitamin D in the range of 200-800 IU is not sufficient for maintaining adequate serum levels of vitamin D [8], it is therefore incumbent upon modern researchers and clinicians to use doses of vitamin D that are consistent with the physiologic requirement as established in current research. Second, the authors recognize that patient compliance in their study population was quite poor. This poor compliance obviously contributed to the purported lack of treatment efficacy. Third, and consistent with recent data published elsewhere [8], virtually all of their patients were still vitamin D deficient at the end of one year of treatment, thereby affirming the inadequacy of the treatment dose. Vitamin D deficiency is common in industrialized nations, particularly those of northern latitudes [9-11], including the UK, where this study was performed. By modern criteria for serum vitamin D levels [12], virtually all of the patients in this study were vitamin D deficient at the beginning of the study, and the insufficient treatment dose of 800 IU/d failed to correct this deficiency even after 1 year of treatment. Given that vitamin D levels must be raised to approximately 40 ng/mL (100 nmol/L) in order to maximally reduce parathyroid hormone levels and bone resorption [13,14], supplementation that does not accomplish the goal of raising serum vitamin D levels into the optimal physiologic range cannot be considered adequate therapy.[12] Fourth, and finally, there is reason to question the bioavailability of their vitamin D3 supplement, as the authors note that their dose-response was generally lower than that seen in other studies. Bioavailability is a prerequisite for treatment efficacy, and the elderly have higher likeliness of comorbid conditions that impair digestion and absorption of nutrients. Specifically, it is well documented that vitamin D absorption is decreased in elderly patients compared to younger controls [15,16], and this is complicated by an age-related reduction in renal calcitriol production [17,18] and intestinal vitamin D receptors [19], thereby further impairing vitamin D metabolism and calcium absorption. Since emulsification of fat soluble vitamins is required for their absorption [20], and since pre-emulsification of nutrients has been shown to increase absorption and dose-responsiveness of the fat-soluble nutrient coenzyme Q [21, 22], it seems apparent that attention to the form (not merely the dose) of nutrient supplementation is clinically important, particularly when working with elderly patients. These shortcomings, when combined, could have lead to an additive or synergistic reduction in treatment potency that skewed their results toward a conclusion of inefficacy. In order to produce more meaningful results in clinical trials, our group published guidelines [12] recommending that future studies 1) ensure patient compliance, 2) use physiologic doses of vitamin D (e.g., 4,000 IU per day), and 3) ensure that serum levels are raised to a minimum of 40 ng/mL (100 nmol/L), since levels below this threshold are associated with increased parathyroid hormone levels, increased bone resorption, and recalcitrance to bone-building interventions.[23,24] Alex Vasquez avasquez@bioticsresearch.com Biotics Research Corporation Rosenberg, Texas, USA 77471

References: 1. Record Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *The Lancet* (Early Online Publication), 28 April 2005 2. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* 2003;77:204-10 3. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr*. 2001;73:288-94 4. Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. *Spine*. 2003;28:177-9 5. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. *Nutr J*. 2004 Jul 19;3(1):8 <http://www.nutritionj.com/content/pdf/1475-2891-3-8.pdf> 6. Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. *J Clin Endocrinol Metab*. 2003;88:4623-32 7. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr*. 1999;69:842-56

<http://www.ajcn.org/cgi/reprint/69/5/842.pdf> 8. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Thomsen J, Charles P, Eriksen EF. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. *J Intern Med.* 2000;247:260-8 9. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. *N Engl J Med* 1998;338:777-83 10. Dubbelman R, Jonxis JH, Muskiet FA, Saleh AE. Age-dependent vitamin D status and vertebral condition of white women living in Curacao (The Netherlands Antilles) as compared with their counterparts in The Netherlands. *Am J Clin Nutr* 1993;58:106-9 11. Kauppinen-Makelin R, Tahtela R, Loyttyneimi E, Karkkainen J, Valimaki MJ. A high prevalence of hypovitaminosis D in Finnish medical in- and outpatients. *J Intern Med.* 2001;249:559-63 12. Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. *Altern Ther Health Med.* 2004;10:28-36; quiz 37, 94 13. Kinyamu HK, Gallagher JC, Rafferty KA, Balhorn KE. Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites. *Am J Clin Nutr* 1998;67:342-8 14. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. *Am J Clin Nutr* 1997;65:67-71 15. Harris SS, Dawson-Hughes B, Perrone GA. Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D. *J Am Coll Nutr.* 1999;18:470-4 16. Barragry JM, France MW, Corless D, Gupta SP, Switala S, Boucher BJ, Cohen RD. Intestinal cholecalciferol absorption in the elderly and in younger adults. *Clin Sci Mol Med.* 1978;55:213-20 17. Tsai KS, Heath H 3rd, Kumar R, Riggs BL. Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. *J Clin Invest.* 1984;73:1668-72 18. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. *J Clin Invest.* 1979;64:729-36 19. Ebeling PR, Sandgren ME, DiMaggio EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. *J Clin Endocrinol Metab.* 1992;75:176-82 20. Gallo-Torres HE. Obligatory role of bile for the intestinal absorption of vitamin E. *Lipids.* 1970;5:379-84 21. Bucci LR, Pillors M, Medlin R, Henderson R, Stiles JC, Robol HJ, Sparks WS. Enhanced uptake in humans of coenzyme Q10 from an emulsified form. *Third International Congress of Biomedical Gerontology; Acapulco, Mexico: June 1989* 22. Bucci LR, Pillors M, Medlin R, Klenda B, Robol H, Stiles JC, Sparks WS. Enhanced blood levels of coenzyme Q-10 from an emulsified oral form. In Faruqui SR and Ansari MS (editors). *Second Symposium on Nutrition and Chiropractic Proceedings.* April 15-16, 1989 in Davenport, Iowa 23. Stepan JJ, Burckhardt P, Hana V. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. *Bone* 2003;33:589-596 24. Vasquez A. Health care for our bones: a practical nutritional approach to preventing osteoporosis. [letter] *J Manipulative Physiol Ther.* 2005;28:213

Competing Interests: Dr. Vasquez is a researcher at Biotics Research Corporation, an FDA-approved drug manufacturing facility in the USA.

References: None

[Back to Top](#)

Viewing 1- of NaN Comments

Comments Page: [1]

[Help](#) | [Feedback](#) | [Privacy Policy](#) | [Terms & Conditions](#) | [Contact Us](#)
Copyright © 2006 [Elsevier Limited](#). All rights reserved.